midazolam has been researched along with metoprolol in 56 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (1.79) | 18.2507 |
2000's | 17 (30.36) | 29.6817 |
2010's | 30 (53.57) | 24.3611 |
2020's | 8 (14.29) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
Jolivette, LJ; Nagilla, R; Ward, KW | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Abraham, MH; Acree, WE; Ibrahim, A | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Sun, Y; Yan, Z | 1 |
Ahman, M; Holmén, AG; Wan, H | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Ahlin, G; Bergström, F; Bredberg, U; Fridén, M; Hammarlund-Udenaes, M; Rehngren, M; Wan, H | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Dalvie, D; Loi, CM; Smith, DA | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Artursson, P; Mateus, A; Matsson, P | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Acevedo, O; Dasararaju, G; Devadasan, V; Halakova, D; Jayaprakash, V; Kovacikova, L; Mohd Siddique, MU; Mondal, SK; Prnova, MS; Shilkar, D; Stefek, M; Thakur, A; Yasmin, S | 1 |
Koscielniak-Nielsen, ZJ | 1 |
Chen, XP; He, N; Huang, SL; Ou-Yang, DS; Tan, ZR; Zhou, HH; Zhu, B | 1 |
Chen, XP; Huang, SL; Huang, Z; Ou-Yang, DS; Tan, ZR; Zhou, HH | 1 |
Harju, K; Ketola, RA; Kostiainen, R; Kotiaho, T; Salo, PK; Salomies, H; Yli-Kauhaluoma, J | 1 |
Ashton, M; Asimus, S; Elsherbiny, D; Hai, TN; Huong, NV; Jansson, B; Petzold, MG; Simonsson, US | 1 |
Hobai, IA | 1 |
Arenz, N; Goltz, L; Kirch, W; Oertel, R; Pietsch, J; Zeitz, SG | 1 |
Guo, C; Han, YL; Jing, GP; Li, D; Li, Y; Meng, XL; Ren, B; Wan, LL; Yu, Q; Zhou, ZY | 1 |
Abduljalil, K; Gaohua, L; Jamei, M; Johnson, TN; Rostami-Hodjegan, A | 1 |
Iwasaki, K; Izumi, H; Kusumoto, S; Mogi, M; Murayama, N; Shimizu, M; Takehara, H; Toda, A; Utoh, M; Yamazaki, H | 1 |
Jiao, J; Li, Q; Liu, Y; Lou, J; Zhang, C | 1 |
Ikeda, K; Kim, S; Koyanagi, T; Murayama, N; Nakanishi, Y; Uehara, S; Uno, Y; Utoh, M; Yamaura, Y; Yamazaki, H; Yano, K | 1 |
Achterbergh, R; Boelen, A; de Vries, EM; Klümpen, HJ; Lammers, LA; Mathôt, RA; Romijn, JA; Soeters, MR; van Nierop, FS | 1 |
Hu, L; Lin, F; Tang, M; Zheng, Y; Zhuang, Z | 1 |
Inoue, T; Sasaki, E; Shimizu, M; Toda, A; Uehara, S; Uno, Y; Utoh, M; Yamazaki, H | 1 |
Berger, B; Derungs, A; Donzelli, M; Haschke, M; Krähenbühl, S; Noppen, C | 1 |
Shida, S; Yamazaki, H | 1 |
Chen, RJ; Ge, NY; Hao, C; Zhang, DF; Zhang, Y; Zhang, YT; Zhu, GH | 1 |
Achterbergh, R; Boelen, A; de Vries, EM; Klümpen, HJ; Lammers, LA; Mathot, RA; Romijn, JA | 1 |
Achterbergh, R; Lammers, LA; Mathôt, RAA; Romijn, JA; van Schaik, RHN | 1 |
Harwood, MD; Jamei, M; Musther, H; Rostami-Hodjegan, A; Turner, DB; Yang, J | 1 |
Inoue, T; Kusama, T; Mogi, M; Sasaki, E; Shimizu, M; Toda, A; Uehara, S; Uno, Y; Utoh, M; Yamazaki, H | 1 |
Coboeken, K; Dallmann, A; Eissing, T; Hempel, G; Ince, I | 1 |
Achterbergh, R; Lammers, LA; Mathôt, RAA; Romijn, JA | 1 |
Chen, RJ; Dong, YY; Huang, CK; Lin, ZF; Sun, R; Sun, W; Wang, Z; Ye, WJ; Zhang, XD | 1 |
Cintra, MACT; Coelho, EB; Cusinato, DAC; Filgueira, GCO; Lanchote, VL; Rocha, A | 1 |
Chung, JY; Hatley, O; Kim, Y; Lee, H; Lee, HA; Rhee, SJ; Yi, S; Yoon, S; Yu, KS | 1 |
Du, HJ; Lin, YP; Tan, WZ; Tang, BE; Wei, YL; Wu, ML; Ying, XQ | 1 |
Krishna, G; LoRusso, PM; Ogasawara, K; Olszanski, AJ; Palmisano, M; Rixe, O; Xu, C; Yin, J | 1 |
Bachmann, F; Bouitbir, J; Duthaler, U; Grandinetti, T; Haschke, M; Hruz, P; Krähenbühl, S; Pfefferkorn, F; Suenderhauf, C | 1 |
Chen, LJ; Chen, XP; Chen, Y; Guo, J; Liou, YL; Tan, ZR; Xu, Y; Zhang, SX; Zhang, W; Zhou, HH | 1 |
Newman, EM; Rowland, A | 1 |
Dong, YY; Huang, CK; Lang, LP; Li, QQ; Qian, JC; Sun, W; Wang, Z; Zhang, XD | 1 |
Chen, SY; Chen, Y; Gong, ZP; Huang, J; Huang, Y; Li, Y; Li, YT; Wang, YL; Yang, HL; Zheng, L | 1 |
2 review(s) available for midazolam and metoprolol
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
A Physiologically Based Pharmacokinetic Model to Predict the Impact of Metabolic Changes Associated with Metabolic Associated Fatty Liver Disease on Drug Exposure.
Topics: Animals; Caffeine; Clozapine; Cytochrome P-450 CYP1A2; Cytochrome P-450 Enzyme System; Dextromethorphan; Metoprolol; Midazolam; Non-alcoholic Fatty Liver Disease; Omeprazole; Rosiglitazone; Warfarin | 2022 |
6 trial(s) available for midazolam and metoprolol
Article | Year |
---|---|
Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Caffeine; Chlorzoxazone; Coumarins; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Humans; Male; Mephenytoin; Metoprolol; Midazolam; Middle Aged | 2007 |
Short-term fasting alters cytochrome P450-mediated drug metabolism in humans.
Topics: Adult; Animals; Caffeine; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Fasting; Gene Expression Regulation, Enzymologic; Humans; Liver; Male; Metabolic Clearance Rate; Metoprolol; Midazolam; Omeprazole; Rats, Wistar; Warfarin; Young Adult | 2015 |
Effects of Cytochrome P450 Inhibition and Induction on the Phenotyping Metrics of the Basel Cocktail: A Randomized Crossover Study.
Topics: Adult; Alkynes; Benzoxazines; Caffeine; Cross-Over Studies; Cyclopropanes; Cytochrome P-450 Enzyme Inhibitors; Genotype; Humans; Losartan; Male; Metoprolol; Midazolam; Omeprazole; Phenotype; Young Adult | 2016 |
Effect of Short-Term Fasting on Systemic Cytochrome P450-Mediated Drug Metabolism in Healthy Subjects: A Randomized, Controlled, Crossover Study Using a Cocktail Approach.
Topics: Administration, Intravenous; Administration, Oral; Adult; Caffeine; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Drug Combinations; Fasting; Healthy Volunteers; Humans; Male; Metoprolol; Midazolam; Omeprazole; Pharmaceutical Preparations; Time Factors; Warfarin; Young Adult | 2017 |
Short-Term Fasting Alters Pharmacokinetics of Cytochrome P450 Probe Drugs: Does Protein Binding Play a Role?
Topics: Administration, Intravenous; Caffeine; Cross-Over Studies; Cytochrome P-450 Enzyme System; Fasting; Humans; Male; Metoprolol; Midazolam; Omeprazole; Pharmaceutical Preparations; Protein Binding; Warfarin | 2018 |
Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Female; Humans; Hydroxycholesterols; Male; Metoprolol; Midazolam; Middle Aged; Neoplasms; Omeprazole; Protein Kinase Inhibitors; Pyrrolidines; Sulfonamides | 2020 |
48 other study(ies) available for midazolam and metoprolol
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
Topics: Administration, Oral; Animals; Area Under Curve; Dogs; Haplorhini; Humans; Models, Statistical; Rats; Software; Species Specificity; Xenobiotics | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
Topics: Air; Animals; Humans; Lung; Organic Chemicals; Probability; Rats; Tissue Distribution; Volatilization | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
Topics: Computational Biology; Drug Discovery; Hepatocytes; Humans; Hydrogen-Ion Concentration; Liver; Metabolic Clearance Rate; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship; Sensitivity and Specificity; Software | 2009 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
Topics: Animals; Biological Transport; Brain; Chemical Phenomena; Dialysis; Hydrogen-Ion Concentration; In Vitro Techniques; Lysosomes; Male; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tissue Distribution | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
Topics: Animals; Brain; Dialysis; HEK293 Cells; High-Throughput Screening Assays; Humans; Pharmaceutical Preparations; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
Non-carboxylic acid inhibitors of aldose reductase based on N-substituted thiazolidinedione derivatives.
Topics: Aldehyde Reductase; Animals; Caco-2 Cells; Catalytic Domain; Dogs; Enzyme Inhibitors; Humans; Hypoglycemic Agents; Madin Darby Canine Kidney Cells; Male; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Protein Binding; Rats, Wistar; Structure-Activity Relationship; Thiazolidinediones | 2021 |
An unusual toxic reaction to axillary block by mepivacaine with adrenaline.
Topics: Absorption; Aged; Akathisia, Drug-Induced; Anesthetics, Local; Anti-Arrhythmia Agents; Antihypertensive Agents; Atrial Fibrillation; Axilla; Cardiovascular Agents; Drug Interactions; Dupuytren Contracture; Epinephrine; Humans; Hypertension; Hypnotics and Sedatives; Intraoperative Complications; Labetalol; Male; Mepivacaine; Metoprolol; Midazolam; Nerve Block; Unconsciousness; Vasoconstrictor Agents | 1998 |
Assessment of cytochrome P450 activity by a five-drug cocktail approach.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Chlorzoxazone; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Male; Mephenytoin; Metoprolol; Midazolam; Mixed Function Oxygenases; Omeprazole; Oxidoreductases, N-Demethylating | 2001 |
Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Asian People; Aspirin; Caffeine; China; Chlorzoxazone; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Isoenzymes; Male; Mephenytoin; Metoprolol; Midazolam; Mixed Function Oxygenases; Oxidoreductases, N-Demethylating; Phenotype; Reference Values; Theophylline | 2003 |
Analysis of small molecules by ultra thin-layer chromatography-atmospheric pressure matrix-assisted laser desorption/ionization mass spectrometry.
Topics: Atmospheric Pressure; Chromatography, Thin Layer; Metoprolol; Midazolam; Models, Molecular; Molecular Weight; Sensitivity and Specificity; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Verapamil | 2005 |
Atrioventricular block induced by indigo carmine.
Topics: Adjuvants, Anesthesia; Adrenergic Agents; Adrenergic beta-Antagonists; Anesthetics, Intravenous; Atrioventricular Block; Blood Pressure; Coloring Agents; Cystoscopy; Electrocardiography; Ephedrine; Female; Heart Rate; Humans; Indigo Carmine; Intraoperative Complications; Male; Metoprolol; Midazolam; Middle Aged; Muscarinic Antagonists; Propanolamines; Propofol; Prostatectomy | 2008 |
Distribution of metoprolol, tramadol, and midazolam in human autopsy material.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cadaver; Chromatography, Liquid; Female; Forensic Medicine; Humans; Least-Squares Analysis; Male; Metoprolol; Midazolam; Middle Aged; Tandem Mass Spectrometry; Tissue Distribution; Tramadol | 2011 |
Evaluation of impact of Herba Erigerontis injection, a Chinese herbal prescription, on rat hepatic cytochrome P450 enzymes by cocktail probe drugs.
Topics: Animals; Area Under Curve; Caffeine; Chlorzoxazone; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drugs, Chinese Herbal; Enzyme Inhibitors; Erigeron; Herb-Drug Interactions; Metoprolol; Midazolam; Rats; Rats, Sprague-Dawley; Tolbutamide | 2012 |
A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4.
Topics: Adult; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Drug Design; Female; Humans; Metoprolol; Midazolam; Models, Biological; Pregnancy; Pregnancy Trimester, Third; Young Adult | 2012 |
Simultaneous pharmacokinetics assessment of caffeine, warfarin, omeprazole, metoprolol, and midazolam intravenously or orally administered to Microminipigs.
Topics: Administration, Oral; Animals; Biological Availability; Caffeine; Chromatography, Liquid; Cytochrome P-450 Enzyme System; Drug Combinations; Female; Humans; Injections, Intravenous; Male; Metoprolol; Midazolam; Models, Animal; Omeprazole; Substrate Specificity; Swine; Swine, Miniature; Tandem Mass Spectrometry; Warfarin | 2012 |
Assessment of effects of IR and IPC on activities of cytochrome P450 isozymes in rats by a five-drug cocktail approach.
Topics: Animals; Caffeine; Chlorzoxazone; Cytochrome P-450 Enzyme System; Drug Combinations; Drug Interactions; Enzyme Activation; Female; Ischemic Preconditioning; Isoenzymes; Liver; Male; Metoprolol; Midazolam; Random Allocation; Rats; Rats, Wistar; Reperfusion Injury; Tolbutamide | 2014 |
Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation.
Topics: Administration, Oral; Age Factors; Animals; Caffeine; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Female; Macaca fascicularis; Male; Metoprolol; Microsomes, Liver; Midazolam; Models, Animal; Models, Biological; Omeprazole; Warfarin | 2015 |
Effect of Dimethoate on the Activity of Hepatic CYP450 Based on Pharmacokinetics of Probe Drugs.
Topics: Animals; Cholinesterase Inhibitors; Cytochrome P-450 Enzyme System; Dimethoate; Gene Expression; Insecticides; Liver; Male; Metoprolol; Midazolam; Phenacetin; Rats, Sprague-Dawley; RNA, Messenger; Tolbutamide | 2015 |
Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (Callithrix jacchus).
Topics: Administration, Intravenous; Administration, Oral; Animals; Biological Availability; Caffeine; Callithrix; Chromatography, Liquid; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Humans; Intestine, Small; Liver; Metoprolol; Midazolam; Models, Animal; Omeprazole; Tandem Mass Spectrometry; Warfarin | 2016 |
Human plasma concentrations of five cytochrome P450 probes extrapolated from pharmacokinetics in dogs and minipigs using physiologically based pharmacokinetic modeling.
Topics: Animals; Cytochrome P-450 Enzyme System; Dogs; Humans; Metoprolol; Midazolam; Models, Biological; Omeprazole; Swine; Swine, Miniature; Warfarin | 2016 |
Effect of Evodiamine on CYP Enzymes in Rats by a Cocktail Method.
Topics: Administration, Oral; Animals; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Herb-Drug Interactions; Liver; Male; Metoprolol; Midazolam; Omeprazole; Phenacetin; Quinazolines; Rats, Sprague-Dawley; Tolbutamide | 2016 |
Fasting-Induced Changes in Hepatic P450 Mediated Drug Metabolism Are Largely Independent of the Constitutive Androstane Receptor CAR.
Topics: Animals; Caffeine; Constitutive Androstane Receptor; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 2; Fasting; Female; Gene Expression Regulation; Inactivation, Metabolic; Liver; Membrane Proteins; Metoprolol; Mice; Mice, Inbred C57BL; Mice, Knockout; Midazolam; Omeprazole; Receptors, Cytoplasmic and Nuclear; Warfarin | 2016 |
The Constraints, Construction, and Verification of a Strain-Specific Physiologically Based Pharmacokinetic Rat Model.
Topics: Adjuvants, Anesthesia; Administration, Intravenous; Animals; Anti-Arrhythmia Agents; Anticonvulsants; Computer Simulation; Diazepam; Hepatocytes; Male; Metabolic Clearance Rate; Metoprolol; Midazolam; Models, Biological; Rats, Sprague-Dawley | 2017 |
Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19.
Topics: Administration, Intravenous; Aging; Animals; Caffeine; Callithrix; Cytochrome P-450 CYP2C19; Genotype; Humans; Male; Metoprolol; Midazolam; Omeprazole; Rifampin; Substrate Specificity; Warfarin | 2018 |
A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways.
Topics: Caffeine; Cytochrome P-450 Enzyme System; Diazepam; Female; Granisetron; Humans; Metoprolol; Metronidazole; Midazolam; Models, Biological; Nifedipine; Ondansetron; Pharmaceutical Preparations; Pregnancy | 2018 |
A UHPLC-MS/MS method coupled with liquid-liquid extraction for the quantitation of phenacetin, omeprazole, metoprolol, midazolam and their metabolites in rat plasma and its application to the study of four CYP450 activities.
Topics: Administration, Oral; Animals; Benzofurans; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Drug Interactions; Liquid-Liquid Extraction; Male; Metoprolol; Midazolam; Omeprazole; Phenacetin; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tandem Mass Spectrometry | 2019 |
LC-MS/MS analysis of the plasma concentrations of a cocktail of 5 cytochrome P450 and P-glycoprotein probe substrates and their metabolites using subtherapeutic doses.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B; Biological Variation, Population; Caffeine; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Healthy Volunteers; Humans; Isoenzymes; Losartan; Male; Metoprolol; Midazolam; Omeprazole; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Terfenadine | 2019 |
Development of a Korean-specific virtual population for physiologically based pharmacokinetic modelling and simulation.
Topics: Adult; Asian People; Computer Simulation; Cytochrome P-450 Enzyme System; Female; Glucuronosyltransferase; Humans; Liver-Specific Organic Anion Transporter 1; Lorazepam; Male; Metoprolol; Midazolam; Middle Aged; Models, Biological; Omeprazole; Rosuvastatin Calcium; Software; Warfarin; Young Adult | 2019 |
Calycosin Influences the Metabolism of Five Probe Drugs in Rats.
Topics: Animals; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drugs, Chinese Herbal; Isoflavones; Medicine, Chinese Traditional; Metoprolol; Midazolam; Omeprazole; Phenacetin; Rats; Tolbutamide | 2020 |
Liver Cirrhosis Affects the Pharmacokinetics of the Six Substrates of the Basel Phenotyping Cocktail Differently.
Topics: Caffeine; Child; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Flurbiprofen; Humans; Liver Cirrhosis; Metoprolol; Midazolam; Omeprazole | 2022 |
Gut microbiota and host Cyp450s co-contribute to pharmacokinetic variability in mice with non-alcoholic steatohepatitis: Effects vary from drug to drug.
Topics: Animals; Chlorzoxazone; Gastrointestinal Microbiome; Metoprolol; Mice; Midazolam; Non-alcoholic Fatty Liver Disease; Omeprazole; Pharmaceutical Preparations; Phenacetin; Tolbutamide | 2022 |
Determination of CYP450 activities in diabetes mellitus rats by a UHPLC-MS/MS method.
Topics: Acetaminophen; Animals; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Experimental; Metoprolol; Midazolam; Phenacetin; Rats; Tandem Mass Spectrometry; Tolbutamide | 2023 |
[Effect of Laportea bulbifera extract on CYP450 enzyme activities in rats by Cocktail probe drug method].
Topics: Animals; Caffeine; Chlorzoxazone; Chromatography, Liquid; Cytochrome P-450 Enzyme System; Metoprolol; Midazolam; Omeprazole; Plant Extracts; Rats; Tandem Mass Spectrometry; Tolbutamide | 2022 |